Karyopharm Therapeutics (KPTI) AI Stock Analysis

• Market Cap: $167.48M
• Dividend Yield: N/A
• Average Volume (3M): 228.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.20
• Revenue Growth: -3.98%
• EPS Growth: -29.94%
• Country: US
• Employees: 279
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -5.71
• Shares Outstanding: 18,343,967
• 10 Day Avg. Volume: 494,784
• 30 Day Avg. Volume: 228,238
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.27
• Price to Sales (P/S): 0.55
• P/FCF Ratio: -1.07
• Enterprise Value/Market Cap: 1.50
• Enterprise Value/Revenue: 1.72
• Enterprise Value/Gross Profit: 1.79
• Enterprise Value/Ebitda: -3.19
• 1Y Price Target: $16.67
• Price Target Upside: 82.58% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -4.84
• Revenue Forecast (FY): $139.15M

• Rating: 54 Neutral
• Price Target: $10.00 ▲(9.53% Upside)
• Action: Reiterated Date: 03/03/26
• Date: Action: Reiterated 03/03/26

Overall score reflects weak financial performance (persistent losses, negative equity, ongoing cash burn) as the main constraint. This is partially offset by strong technical momentum and a mixed earnings outlook with cost reductions and meaningful upcoming clinical catalysts, but a negative P/E and no dividend limit valuation support.

Positive Factors

High product gross margins

Very high product-level gross margins (~96–98%) indicate that XPOVIO has strong unit economics, providing structural leverage as revenue grows. Durable margin strength supports reinvestment in trials, pricing flexibility, and improves the potential for future profitability if operating losses and SG&A are controlled.

Established commercial revenue base

A recurring commercial franchise (U.S. XPOVIO ~$115M in FY25) plus partner/license income provides a durable revenue foundation. This diversified cash generation (product sales + partner receipts) reduces sole dependence on new approvals and supports ongoing R&D and late‑stage program funding near term.

Operating cost discipline

Meaningful reductions in R&D and SG&A demonstrate management focus on prioritizing late‑stage programs and cutting discretionary spend. Sustained cost discipline can extend runway, reduce dilution needs, and improve the odds that pivotal programs reach readout with a smaller incremental financing requirement.

Negative Factors

Negative shareholders' equity

Persistently negative shareholders' equity is a structural capitalization issue that constrains financing options, may force dilutive raises, and signals accumulated losses. Negative equity reduces flexibility for M&A, licensing deals, or debt capacity and raises long‑term solvency concerns absent sustained profitability or external funding.

Ongoing cash burn & tight runway

Consistent negative operating and free cash flow, and year‑end cash falling to $64.1M with runway only into Q2 2026, create a durable financing overhang. The company must access capital near binary Phase III readouts, weakening negotiating leverage and increasing execution risk if trial timing or results shift.

High interest expense & debt charges

Elevated interest costs and large debt‑related charges materially increase GAAP losses and consume cash. This structural financing burden reduces funds available for operations, makes future borrowing more expensive, and amplifies earnings volatility from nonoperational items, pressuring long‑term financial durability.

Karyopharm Therapeutics Business Overview & Revenue Model

Company Description

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

How the Company Makes Money

Karyopharm Therapeutics generates revenue primarily through the commercialization of its lead product, Xpovio, which has received approval from regulatory authorities for treating certain types of cancers. The company earns money through direct product sales to healthcare providers and patients. In addition, Karyopharm may also generate revenue from collaborations and partnerships with other pharmaceutical companies, which could include licensing agreements, research and development collaborations, and milestone payments. These partnerships often enable Karyopharm to share the costs and risks associated with drug development while providing additional financial resources that contribute to the company's overall earnings.

Karyopharm Therapeutics Financial Statement Overview

Summary

Financials remain pressured: revenue is roughly flat, operating results and net losses are deeply negative (worsening in 2025), shareholders’ equity is consistently negative, and operating/free cash flow are negative despite some reduction in operating cash burn. Strong gross margins do not translate into sustainable profitability, and capitalization strain elevates risk.

Income Statement

Revenue has been essentially flat in recent years (2024 ~-0.5% and 2025 +2.5% vs. prior year), following declines in 2022–2023. Despite very strong gross margins (~96–98%), profitability remains weak: operating results are deeply negative each year and net losses are substantial, with 2025 deteriorating meaningfully versus 2024 (net margin ~-134% vs. ~-53%). Overall, the business shows good product-level economics but has not translated that into sustainable earnings.

Balance Sheet

The balance sheet is pressured by consistently negative shareholders’ equity (2021–2025), which raises financial risk and limits flexibility. Debt is meaningful and has fluctuated (down from 2024 to 2025), but negative equity makes leverage metrics less informative and highlights capitalization strain. Total assets have also trended down notably from 2022 to 2025, suggesting a shrinking balance sheet alongside ongoing losses.

Cash Flow

Cash generation is a key concern: operating cash flow and free cash flow are negative every year shown, indicating ongoing cash burn. There is some improvement versus 2024 (operating cash burn reduced in 2025), but free cash flow growth in 2025 is sharply negative versus the prior year, reflecting volatility and continued funding needs. Overall, cash flow trends do not yet support self-funded operations.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	146.07M	145.24M	146.03M	157.07M	209.82M
Gross Profit	140.12M	139.23M	141.09M	151.86M	206.42M
EBITDA	-90.41M	-38.60M	-118.42M	-139.31M	-96.98M
Net Income	-196.04M	-76.42M	-143.10M	-165.29M	-124.09M
Balance Sheet
Total Assets	108.42M	164.42M	240.44M	358.17M	305.31M
Cash, Cash Equivalents and Short-Term Investments	63.74M	108.71M	191.44M	277.97M	228.62M
Total Debt	233.61M	194.52M	177.02M	179.07M	180.58M
Total Liabilities	401.34M	350.44M	376.64M	374.83M	384.98M
Stockholders Equity	-292.93M	-186.02M	-136.21M	-16.66M	-79.67M
Cash Flow
Free Cash Flow	-75.37M	-127.63M	-92.72M	-149.67M	-112.83M
Operating Cash Flow	-75.37M	-127.49M	-92.72M	-149.55M	-107.12M
Investing Cash Flow	43.38M	95.47M	7.94M	-104.26M	141.84M
Financing Cash Flow	30.05M	41.65M	1.12M	193.74M	73.65M

Karyopharm Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.13
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KPTI, the sentiment is Positive. The current price of 9.13 is above the 20-day moving average (MA) of 8.43, above the 50-day MA of 7.64, and above the 200-day MA of 5.97, indicating a bullish trend. The MACD of 0.71 indicates Negative momentum. The RSI at 58.19 is Neutral, neither overbought nor oversold. The STOCH value of 31.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KPTI.

Karyopharm Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KPTI	54 Neutral	$167.48M	-0.55	―	―	-3.98%	-29.94%
IPSC	54 Neutral	$409.60M	-7.33	-14.23%	―	4121.12%	83.30%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LTRN	50 Neutral	$30.31M	-1.55	-104.58%	―	―	1.18%
BTAI	47 Neutral	$34.99M	-0.16	―	―	-66.96%	71.83%
ATNM	45 Neutral	$34.63M	-1.00	-133.09%	―	11.11%	20.65%
MDCX	45 Neutral	$37.56M	-0.70	-2237.54%	―	―	-55.95%

Karyopharm Therapeutics Corporate Events

Karyopharm Amends Credit Agreement to Extend Liquidity Runway

On February 27, 2026, Karyopharm Therapeutics Inc. amended its existing Credit and Guaranty Agreement to reduce near-term cash outflows and extend its liquidity runway beyond the second quarter of 2026, aligning with the anticipated mid-2026 readout of top-line data from its Phase 3 XPORT-EC 042 trial. The Second Amendment allows deferral of certain principal and interest payments to September 2026, maintains a $10 million minimum liquidity covenant through October 10, 2026, and prevents specified equity raise proceeds from increasing that covenant, while also extending a 5% prepayment premium window if a qualifying $25 million capital raise is completed before June 10, 2026.

The most recent analyst rating on (KPTI) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Karyopharm Therapeutics stock, see the KPTI Stock Forecast page.

Karyopharm Shareholders Approve Major Authorized Share Increase

On February 18, 2026, Karyopharm Therapeutics Inc. stockholders approved an amendment to the company’s Restated Certificate of Incorporation to increase total authorized capital stock from 58,333,333 to 111,000,000 shares and authorized common stock from 53,333,333 to 106,000,000 shares. The company filed the corresponding Certificate of Amendment with the Delaware Secretary of State that same day, significantly expanding its capacity to issue new shares for potential future financing or strategic purposes.

At the same February 18, 2026 Special Meeting, stockholders also approved a proposal that would have allowed adjournment of the meeting to solicit additional proxies if support for the share increase had been insufficient. Because a quorum was present and votes in favor of the Authorized Shares Proposal were adequate, adjournment proved unnecessary, underscoring strong shareholder backing for the capital structure expansion.

The most recent analyst rating on (KPTI) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Karyopharm Therapeutics stock, see the KPTI Stock Forecast page.

Karyopharm Issues Preliminary 2025 Financial Results and Outlook

On January 12, 2026, Karyopharm reported preliminary unaudited financial results indicating it expects approximately $33 million in total revenue for the fourth quarter of 2025 and about $145 million for full-year 2025, including $32 million and $115 million, respectively, in U.S. XPOVIO net product revenue. The company ended 2025 with roughly $64 million in cash, cash equivalents, restricted cash and investments, and, along with anticipated product and license revenue, believes it can fund operations into the second quarter of 2026, supported by strategic financings that extended its cash runway beyond the upcoming Phase 3 SENTRY myelofibrosis readout. Operationally, Karyopharm completed enrollment of the Phase 3 SENTRY trial in myelofibrosis in September 2025, continued global expansion and steady demand for XPOVIO in a competitive multiple myeloma market, advanced Phase 2 and Phase 3 selinexor programs in myelofibrosis, and refined the design and enrollment of its Phase 3 XPORT-EC-042 endometrial cancer trial, setting up 2026 as a catalyst-heavy year with two major Phase 3 data readouts that could materially influence its position in oncology and long-term value for stakeholders.

The most recent analyst rating on (KPTI) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Karyopharm Therapeutics stock, see the KPTI Stock Forecast page.